TNFRSF18 and Miyoshi myopathy: Importantly, treatment of MM patients’ (N = 10) BMMC with the specific mAb targeting PD1, LAG3, OX40, or GITR induced upregulation of PD1 and LAG3 expression on T cells (Fig. 5A; histograms, bar graph).